Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 7
2013 11
2014 4
2015 4
2016 3
2017 3
2018 5
2019 7
2020 7
2021 9
2022 10
2023 10
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group. Grebely J, et al. Among authors: read p. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6. Lancet Gastroenterol Hepatol. 2018. PMID: 29310928 Free article. Clinical Trial.
Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis.
Koopsen J, Matthews G, Rockstroh J, Applegate TL, Bhagani S, Rauch A, Grebely J, Sacks-Davis R, Ingiliz P, Boesecke C, Rebers S, Feld J, Bruneau J, Martinello M, Hellard M, Dore GJ, Schinkel J, van der Valk M; REACT Study Group. Koopsen J, et al. Lancet Microbe. 2023 Aug;4(8):e622-e631. doi: 10.1016/S2666-5247(23)00108-8. Epub 2023 Jun 16. Lancet Microbe. 2023. PMID: 37336226 Free article.
A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study.
Conway A, Valerio H, Alavi M, Silk D, Treloar C, Hajarizadeh B, Marshall AD, Martinello M, Milat A, Dunlop A, Murray C, Prain B, Henderson C, Amin J, Read P, Marks P, Degenhardt L, Hayllar J, Reid D, Gorton C, Lam T, Christmass M, Wade A, Montebello M, Dore GJ, Grebely J; ETHOS Engage Study Group. Conway A, et al. Among authors: read p. Viruses. 2022 Jul 16;14(7):1555. doi: 10.3390/v14071555. Viruses. 2022. PMID: 35891535 Free PMC article.
Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study.
Wheeler A, Valerio H, Cunningham EB, Martinello M, Barocas JA, Colledge-Frisby S, Treloar C, Amin J, Henderson C, Read P, Matthews GV, Dunlop AJ, Gorton C, Hayllar J, Alavi M, Murray C, Marks P, Silk D, Degenhardt L, Dore GJ, Grebely J; ETHOS Engage Study Group. Wheeler A, et al. Among authors: read p. Drug Alcohol Depend. 2022 Aug 1;237:109543. doi: 10.1016/j.drugalcdep.2022.109543. Epub 2022 Jun 26. Drug Alcohol Depend. 2022. PMID: 35772249
Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
Valerio H, Alavi M, Conway A, Silk D, Treloar C, Martinello M, Milat A, Dunlop A, Murray C, Henderson C, Amin J, Read P, Marks P, Degenhardt L, Stevens A, Prain B, Hayllar J, Reid D, Montebello M, Wade A, Christmass M, Cock V, Dore GJ, Grebely J; ETHOS Engage Study Group. Valerio H, et al. Among authors: read p. Int J Drug Policy. 2022 Jul;105:103706. doi: 10.1016/j.drugpo.2022.103706. Epub 2022 May 6. Int J Drug Policy. 2022. PMID: 35533635
High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study.
Yee J, Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Doyle JS, Davies J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH‐C Study Group. Yee J, et al. Among authors: read p. Hepatol Commun. 2022 Mar;6(3):496-512. doi: 10.1002/hep4.1826. Epub 2021 Nov 2. Hepatol Commun. 2022. PMID: 34729957 Free PMC article.
Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study.
Conway A, Read P, Gilliver R, McNaughton T, Valerio H, Cunningham EB, Henderson C, Hadlow B, Molloy K, Doab A, Tillakeratne S, Pepolim L, Harrod ME, Dore GJ, Grebely J. Conway A, et al. Among authors: read p. Viruses. 2022 Nov 7;14(11):2463. doi: 10.3390/v14112463. Viruses. 2022. PMID: 36366561 Free PMC article.
Low Prior Exposure and Incidence of Hepatitis C in Human Immunodeficiency Virus-Negative Gay and Bisexual Men Taking Preexposure Prophylaxis (PrEP): Findings From the Expanded PrEP Implementation in Communities-New South Wales Prospective Implementation Study.
Amin J, Vaccher S, Templeton DJ, Bavinton B, Jin F, Zablotska I, Matthews G, Ogilvie E, Yeung B, Ooi C, Dharan N, Baker DA, Read P, Guy R, Grulich AE. Amin J, et al. Among authors: read p. Clin Infect Dis. 2022 Oct 29;75(9):1497-1502. doi: 10.1093/cid/ciac231. Clin Infect Dis. 2022. PMID: 35352102
84 results